Literature DB >> 11253603

Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.

M Weiss1.   

Abstract

In the last 30 years, a multitude of treatment regimens for adult acute lymphocytic leukemia (ALL) has been developed. Essentially, all of these regimens use an induction therapy vincristine, prednisone, and an anthracycline intensified with L-asparaginase or cyclophosphamide. Though such regimens induce most patients to enter a remission, relapse is frequent, and most adult patients ultimately die of their disease. The author postulated that further refinements in this approach to induction therapy were unlikely to markedly improve treatment results in this disease. Therefore, the author is studying a new intensive strategy using cytarabine with a single very high dose of mitoxantrone (without vincristine or prednisone) as induction therapy for adult patients with ALL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253603     DOI: 10.1016/s0889-8588(05)70196-9

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  1 in total

1.  Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.

Authors:  Hernan Carol; Mannie M Y Fan; Troy O Harasym; Ingrid Boehm; Lawrence D Mayer; Peter Houghton; Malcolm A Smith; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2014-09-09       Impact factor: 3.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.